In this free webinar, learn about the critical role of imaging biomarkers in characterizing patient eligibility, safety and therapeutic efficacy in Alzheimer's disease (AD) clinical trials. Attendees will gain insights into endpoint collection for clinical outcome assessments (COAs) in a changing patient population. The featured speakers will also underscore the importance of sufficient baseline testing in a population at high risk for cardiovascular disease independent of the drug being investigated.
TORONTO, May 30, 2024 /PRNewswire-PRWeb/ -- Join this webinar, which explores the critical aspects of conducting clinical trials in Alzheimer's disease (AD), focusing on innovative methodologies and challenges encountered. The speakers will review the pivotal role of imaging biomarkers in characterizing patient eligibility, ensuring safety and evaluating therapeutic efficacy in AD trials.
Next, the presentation will discuss the evolving landscape and challenges of collecting endpoints for clinical outcome assessments (COAs) in a changing patient population. From there onwards, the potential of leveraging gait and balance measures for the detection and diagnosis of cognitive impairment and dementia and their significance in early intervention will be discussed.
Finally, the speakers will review the complexities of running trials in populations at high risk for cardiovascular (CV) disease, emphasizing the importance of baseline testing regardless of the drug being investigated.
Register for this webinar today to gain insights that can inform sponsors to enhance the design and execution of AD clinical trials.
Join experts from Clario, (Moderator) Todd Rudo, MD, Chief Medical Officer, Chris Conklin, Senior MRI Scientist, Neuroscience, Dr. Prateek Verma, Director, eCOA Science & Consulting, Vic Patel, Vice President & Chief Medical Officer, Cardiology; and Adam Jagodinksy, Scientific Advisor, Precision Motion, for the live webinar on Thursday, June 13, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Advancing Alzheimer's Clinical Trial Endpoints: Imaging Biomarkers, COA Challenges, Movement Measures, and CV Risk.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, skumar@xtalks.com, https://xtalks.com
SOURCE Xtalks
